<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044772</url>
  </required_header>
  <id_info>
    <org_study_id>0600B5-399</org_study_id>
    <nct_id>NCT00044772</nct_id>
  </id_info>
  <brief_title>Study Evaluating Venlafaxine ER in Patients With Panic Disorder</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine
      extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in
      comparison to those of placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">653</enrollment>
  <condition>Panic Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine ER</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before
             study day 1

          -  Have sufficient symptoms to require anxiolytic drug therapy

          -  Have a score â‰¥4 on the Clinical Global Impressions Scale (CGI) severity of illness
             item at screening and baseline

        Exclusion Criteria:

          -  Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine

          -  History or presence of any clinically important hepatic, renal, or other medical
             disease that might compromise the study or be detrimental to the patient (eg,
             clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal
             cell epithelioma], uncontrolled hypertension)

          -  Clinically important abnormality on screening physical examination, vital signs,
             electrocardiogram (ECG), laboratory tests or urine drug screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2002</study_first_submitted>
  <study_first_submitted_qc>September 5, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2002</study_first_posted>
  <last_update_submitted>August 13, 2009</last_update_submitted>
  <last_update_submitted_qc>August 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2009</last_update_posted>
  <keyword>Panic</keyword>
  <keyword>Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

